




The relative strengths and weaknesses of Trius Therapeutics Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Trius Therapeutics Inc compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 70% points. The greatest weakness of Trius Therapeutics Inc is the variable Research and Development, reducing the Economic Capital Ratio by 63% points.

The company's Economic Capital Ratio, given in the ranking table, is 267%, being 47% points above the market average of 220%.

Input Variable	Value in 1000 USD
Assets, Current	73,981
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	18,487
Liabilities, Non-Current	0
Other Assets	303
Other Compr. Net Income	2.0
Other Expenses	0
Other Liabilities	0
Other Net Income	3,305
Other Revenues	27,185
Property and Equipment	990
Research and Development	69,023
Selling, General and Administrative Expense	15,395

Output Variable	Value in 1000 USD
Assets	75,274
Liabilities	18,487
Expenses	84,418
Revenues	27,185
Stockholders Equity	56,787
Net Income	-53,928
Comprehensive Net Income	-53,927
BaseVar	104,336
ECR before Limited Liability	149%
Economic Capital Ratio	267%